Jaskowski Luke N, Clanton Nicholas A, Wilkinson Nancy J, Bartels Jennifer L, LoCoco Peter M, Frantz Amber N, Boyer Andrew D, Boerma Joseph W, Bush Jycole E M, Brown Seth D, Fernandez Kayylen, Archer Noel E, Tekin Volkan, Fernandez Solana R, Risinger April L, Frantz Doug E, Lapi Suzanne E
Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama 35233, United States.
Voelcker Preclinical Pharmacology Core, University of Texas at San Antonio, San Antonio, Texas 78249, United States.
ACS Med Chem Lett. 2025 Jul 16;16(8):1569-1574. doi: 10.1021/acsmedchemlett.5c00208. eCollection 2025 Aug 14.
The taccalonolides are plant-derived microtubule stabilizers that covalently and specifically bind β-tubulin and provide antitumor efficacy in drug-resistant tumor models both in vitro and in vivo. Herein, we report the radiolabeling, in vitro uptake, and in vivo imaging of a F radiolabeled taccalonolide to investigate in vivo biodistribution, including accumulation in TNBC tumors. Biochemical and cellular studies demonstrate that fluorination does not alter biological activity and supports target engagement of the radiolabeled compound. In vivo studies in athymic nude mice bearing TNBC xenografts and healthy control animals show the highest uptake in the gallbladder and intestines with modest uptake in tumors. Unmodified free drug was detected in the gall bladder and intestines, suggesting hepatic transport of the compound prior to metabolism or irreversible target engagement. These results provide a strong rationale for the generation of novel derivatives and formulations to improve serum half-life and tumor targeting of the taccalonolides to ultimately provide new options for drug-resistant TNBC tumors.
他卡诺内酯是植物来源的微管稳定剂,可与β-微管蛋白共价且特异性结合,并在体外和体内的耐药肿瘤模型中发挥抗肿瘤功效。在此,我们报告了一种氟放射性标记的他卡诺内酯的放射性标记、体外摄取及体内成像情况,以研究其体内生物分布,包括在三阴性乳腺癌(TNBC)肿瘤中的蓄积。生化和细胞研究表明,氟化不会改变生物活性,并支持放射性标记化合物与靶点的结合。在携带TNBC异种移植瘤的无胸腺裸鼠和健康对照动物中进行的体内研究显示,胆囊和肠道摄取量最高,肿瘤摄取量适中。在胆囊和肠道中检测到未修饰的游离药物,这表明该化合物在代谢或不可逆的靶点结合之前先经肝脏转运。这些结果为开发新型衍生物和制剂以改善他卡诺内酯的血清半衰期和肿瘤靶向性提供了有力依据,最终为耐药TNBC肿瘤提供新的治疗选择。